Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting

Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting

Dulaglutide (Trulicity) treatment of patients with type 2 diabetes (T2D) and moderate to severe chronic kidney disease was associated with lesser estimated glomerular filtration rate (eGFR) decline compared to insulin glargine (glargine) in a clinical trial. This study examined the relationship betw...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1)
Hauptverfasser: BOYE, KRISTINA, MODY, REEMA, WU, JIANMIN, LAGE, MAUREEN J., BOTROS, FADY T., WOODWARD, BRAD
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Diabetes (New York, N.Y.)
container_volume 67
creator BOYE, KRISTINA
MODY, REEMA
WU, JIANMIN
LAGE, MAUREEN J.
BOTROS, FADY T.
WOODWARD, BRAD
description Dulaglutide (Trulicity) treatment of patients with type 2 diabetes (T2D) and moderate to severe chronic kidney disease was associated with lesser estimated glomerular filtration rate (eGFR) decline compared to insulin glargine (glargine) in a clinical trial. This study examined the relationship between dulaglutide or glargine use and eGFR for adults with T2D using real-world data from a U.S. electronic health records from 10/25/2013 to 6/18/2017. There were 13,869 glargine and 1,222 dulaglutide patients included in the descriptive analyses. Patients with initial eGFR < 60 or < 30 mL/min/1.73m2 were more likely to be treated with glargine than dulaglutide (31.3% v 17.1%, p
doi_str_mv 10.2337/db18-1557-P
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_2337_db18_1557_P</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2337_db18_1557_P</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_2337_db18_1557_P3</originalsourceid><addsrcrecordid>eNqVj8tKBDEQRYMo2D5W_kDtJZp0GGOvtUdnN4yC7kKcVJpoJpFKeuHfmwZ_QGpxoe4DDmNXUtz0Sulb9yHvuVytNN8esU4OauCq1-_HrBNC9lzqQZ-ys1I-hRB37Tr2NXqP-1oge3ico53iXINDsMnBJpU5hgRP0dIUEkJOMJYaDraia998QGoVgnWIlWwNzd81D1rHwg5t5G-ZooMXrDWk6YKdeBsLXv7pObtej68Pz3xPuRRCb76pjdOPkcIsPGbhMQuP2ar_pX8BbO9S7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>BOYE, KRISTINA ; MODY, REEMA ; WU, JIANMIN ; LAGE, MAUREEN J. ; BOTROS, FADY T. ; WOODWARD, BRAD</creator><creatorcontrib>BOYE, KRISTINA ; MODY, REEMA ; WU, JIANMIN ; LAGE, MAUREEN J. ; BOTROS, FADY T. ; WOODWARD, BRAD</creatorcontrib><description>Dulaglutide (Trulicity) treatment of patients with type 2 diabetes (T2D) and moderate to severe chronic kidney disease was associated with lesser estimated glomerular filtration rate (eGFR) decline compared to insulin glargine (glargine) in a clinical trial. This study examined the relationship between dulaglutide or glargine use and eGFR for adults with T2D using real-world data from a U.S. electronic health records from 10/25/2013 to 6/18/2017. There were 13,869 glargine and 1,222 dulaglutide patients included in the descriptive analyses. Patients with initial eGFR &lt; 60 or &lt; 30 mL/min/1.73m2 were more likely to be treated with glargine than dulaglutide (31.3% v 17.1%, p&lt;0.01; 5.3% v 1.0%, p&lt;0.01, respectively). Multivariable analyses on a matched cohort (N=2,366) found dulaglutide use, compared to glargine use, was associated with a significantly smaller decline in eGFR and a smaller proportion of patients with ≥30% decline in eGFR in the 1-year post-period (Figure 1). With the caveat of limited numbers of patients with severe renal impairment, dulaglutide treatment, compared to glargine, was associated with a smaller decline in renal function in a real-world setting.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db18-1557-P</identifier><language>eng</language><ispartof>Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids></links><search><creatorcontrib>BOYE, KRISTINA</creatorcontrib><creatorcontrib>MODY, REEMA</creatorcontrib><creatorcontrib>WU, JIANMIN</creatorcontrib><creatorcontrib>LAGE, MAUREEN J.</creatorcontrib><creatorcontrib>BOTROS, FADY T.</creatorcontrib><creatorcontrib>WOODWARD, BRAD</creatorcontrib><title>Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting</title><title>Diabetes (New York, N.Y.)</title><description>Dulaglutide (Trulicity) treatment of patients with type 2 diabetes (T2D) and moderate to severe chronic kidney disease was associated with lesser estimated glomerular filtration rate (eGFR) decline compared to insulin glargine (glargine) in a clinical trial. This study examined the relationship between dulaglutide or glargine use and eGFR for adults with T2D using real-world data from a U.S. electronic health records from 10/25/2013 to 6/18/2017. There were 13,869 glargine and 1,222 dulaglutide patients included in the descriptive analyses. Patients with initial eGFR &lt; 60 or &lt; 30 mL/min/1.73m2 were more likely to be treated with glargine than dulaglutide (31.3% v 17.1%, p&lt;0.01; 5.3% v 1.0%, p&lt;0.01, respectively). Multivariable analyses on a matched cohort (N=2,366) found dulaglutide use, compared to glargine use, was associated with a significantly smaller decline in eGFR and a smaller proportion of patients with ≥30% decline in eGFR in the 1-year post-period (Figure 1). With the caveat of limited numbers of patients with severe renal impairment, dulaglutide treatment, compared to glargine, was associated with a smaller decline in renal function in a real-world setting.</description><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqVj8tKBDEQRYMo2D5W_kDtJZp0GGOvtUdnN4yC7kKcVJpoJpFKeuHfmwZ_QGpxoe4DDmNXUtz0Sulb9yHvuVytNN8esU4OauCq1-_HrBNC9lzqQZ-ys1I-hRB37Tr2NXqP-1oge3ico53iXINDsMnBJpU5hgRP0dIUEkJOMJYaDraia998QGoVgnWIlWwNzd81D1rHwg5t5G-ZooMXrDWk6YKdeBsLXv7pObtej68Pz3xPuRRCb76pjdOPkcIsPGbhMQuP2ar_pX8BbO9S7w</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>BOYE, KRISTINA</creator><creator>MODY, REEMA</creator><creator>WU, JIANMIN</creator><creator>LAGE, MAUREEN J.</creator><creator>BOTROS, FADY T.</creator><creator>WOODWARD, BRAD</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20180701</creationdate><title>Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting</title><author>BOYE, KRISTINA ; MODY, REEMA ; WU, JIANMIN ; LAGE, MAUREEN J. ; BOTROS, FADY T. ; WOODWARD, BRAD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_2337_db18_1557_P3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BOYE, KRISTINA</creatorcontrib><creatorcontrib>MODY, REEMA</creatorcontrib><creatorcontrib>WU, JIANMIN</creatorcontrib><creatorcontrib>LAGE, MAUREEN J.</creatorcontrib><creatorcontrib>BOTROS, FADY T.</creatorcontrib><creatorcontrib>WOODWARD, BRAD</creatorcontrib><collection>CrossRef</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BOYE, KRISTINA</au><au>MODY, REEMA</au><au>WU, JIANMIN</au><au>LAGE, MAUREEN J.</au><au>BOTROS, FADY T.</au><au>WOODWARD, BRAD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2018-07-01</date><risdate>2018</risdate><volume>67</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Dulaglutide (Trulicity) treatment of patients with type 2 diabetes (T2D) and moderate to severe chronic kidney disease was associated with lesser estimated glomerular filtration rate (eGFR) decline compared to insulin glargine (glargine) in a clinical trial. This study examined the relationship between dulaglutide or glargine use and eGFR for adults with T2D using real-world data from a U.S. electronic health records from 10/25/2013 to 6/18/2017. There were 13,869 glargine and 1,222 dulaglutide patients included in the descriptive analyses. Patients with initial eGFR &lt; 60 or &lt; 30 mL/min/1.73m2 were more likely to be treated with glargine than dulaglutide (31.3% v 17.1%, p&lt;0.01; 5.3% v 1.0%, p&lt;0.01, respectively). Multivariable analyses on a matched cohort (N=2,366) found dulaglutide use, compared to glargine use, was associated with a significantly smaller decline in eGFR and a smaller proportion of patients with ≥30% decline in eGFR in the 1-year post-period (Figure 1). With the caveat of limited numbers of patients with severe renal impairment, dulaglutide treatment, compared to glargine, was associated with a smaller decline in renal function in a real-world setting.</abstract><doi>10.2337/db18-1557-P</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)
issn 0012-1797
1939-327X
language eng
recordid cdi_crossref_primary_10_2337_db18_1557_P
source EZB-FREE-00999 freely available EZB journals; PubMed Central
title Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A12%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Dulaglutide%20and%20Insulin%20Glargine%20on%20Estimated%20Glomerular%20Filtration%20Rate%20in%20a%20Real-World%20Setting&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=BOYE,%20KRISTINA&rft.date=2018-07-01&rft.volume=67&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db18-1557-P&rft_dat=%3Ccrossref%3E10_2337_db18_1557_P%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true